Zhang Yalei, Li Ye, Chen Kun, Qian Ling, Wang Peng
Department of Integrative Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
J Cancer Res Ther. 2022 Sep;18(5):1247-1255. doi: 10.4103/jcrt.jcrt_91_21.
Emerging evidence has revealed the critical role of the tumor microenvironment (TME) in tumor progression, angiogenesis, metastasis, and immunosuppression. Oncolytic viruses (OVs), a versatile therapeutic agent that targets both cancer cells and the TME, have emerged as a promising candidate for antitumor therapy. Strategies of manipulating OVs against the TME include normalization of the tumor vasculature, decomposition of the tumor stroma, and reversion of the immunosuppressive microenvironment. In pancreatic cancer, desmoplastic stroma comprises up to 80% of the tumor mass, accompanied by hypovascularity and profound immunosuppression, conferring a particularly important role to TME-targeted oncolytic virotherapy. Mechanisms and supporting evidence of OVs reversing the tumor-privileged TME and applications of TME-targeted OVs for pancreatic cancer are summarized in this review.
新出现的证据揭示了肿瘤微环境（TME）在肿瘤进展、血管生成、转移和免疫抑制中的关键作用。溶瘤病毒（OVs）是一种靶向癌细胞和TME的多功能治疗剂，已成为抗肿瘤治疗的有希望的候选者。针对TME操纵OVs的策略包括肿瘤血管正常化、肿瘤基质分解和免疫抑制微环境的逆转。在胰腺癌中，促结缔组织增生性基质占肿瘤质量的80%，伴有血管减少和深度免疫抑制，这赋予了靶向TME的溶瘤病毒疗法特别重要的作用。本文综述了OVs逆转肿瘤特惠TME的机制和支持证据以及靶向TME的OVs在胰腺癌中的应用。
